Towards therapeutic stimulations of gd T cells

Most vaccine strategies are designed to elicit adaptive immune responses to a variety of microbial or tumor-associated antigens. These immune responses are predominantly mediated by αβ T cells, B cells and antibodies. Nevertheless, approximately 1-5% of human peripheral blood lymphocytes possess the surface gd T-cell receptor, predominantly expressing the Vγ9Vδ2 variable segments.